| Budget Amount *help |
¥113,620,000 (Direct Cost: ¥87,400,000、Indirect Cost: ¥26,220,000)
Fiscal Year 2019: ¥23,270,000 (Direct Cost: ¥17,900,000、Indirect Cost: ¥5,370,000)
Fiscal Year 2018: ¥23,400,000 (Direct Cost: ¥18,000,000、Indirect Cost: ¥5,400,000)
Fiscal Year 2017: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2016: ¥22,490,000 (Direct Cost: ¥17,300,000、Indirect Cost: ¥5,190,000)
Fiscal Year 2015: ¥21,970,000 (Direct Cost: ¥16,900,000、Indirect Cost: ¥5,070,000)
|
|---|
| Outline of Final Research Achievements |
BLT1, a receptor for leukotriene B4, is expressed in M2 macrophages and exacerbates pathological angiogenesis in age-related macular degeneration (AMD) and allergic conjunctivitis in mice. BLT2, a receptor for leukotriene B4, 12-hydroxyheptadecatrienoic acid, and other fatty acids, is expressed in the epithelium of the skin and cornea and plays positive roles in maintenance and repair of epithelial barrier function. In addition, BLT2 was found to be expressed in pulmonary vascular endothelial cells and prevented individual death due to acute lung injury caused by bacterial toxins including pneumolysis. A diet rich in omega-3 fatty acids inhibited allergic inflammatory responses by competing the omega-6 fatty acid metabolic pathways. Total organic synthesis methods for novel lipid mediators derived from omega-3 fatty acids were established.
|
